Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4146064 | 1.00 | PRKCA (0.38) | PRKCAMMP12ALOX5APGPR84HRH3 | |
| SCHEMBL4145232 | 0.94 | HRH3 (0.33) | PRKCAMMP12ALOX5APGPR84HRH3 | |
| SCHEMBL4145227 | 0.94 | HRH3 (0.33) | PRKCAMMP12ALOX5APGPR84HRH3 | |
| SCHEMBL4144329 | 0.92 | MET (0.38) | ALOX5APGPR84HRH3MCHR1MET | |
| SCHEMBL4144331 | 0.92 | MET (0.38) | ALOX5APGPR84HRH3MCHR1MET | |
| SCHEMBL4151555 | 0.92 | PRKCA (0.39) | PRKCAMMP12SLC6A5 | |
| SCHEMBL4151551 | 0.92 | PRKCA (0.39) | PRKCAMMP12SLC6A5 | |
| SCHEMBL4156439 | 0.90 | SLC6A5 (0.38) | PRKCAMMP12GPR84SLC6A5 | |
| SCHEMBL4145072 | 0.90 | P2RY12 (0.39) | GPR84HRH3METMAPK14SMO | |
| SCHEMBL4145071 | 0.90 | P2RY12 (0.39) | GPR84HRH3METMAPK14SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | PRKCA 4320/4885MMP12 3563/4885ALOX5AP 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.